VJVirtual | Opportunities to improve CAR-T outcomes
Jordan Gauthier
• 30 Mar 2020
Jordan Gauthier, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, tells us how CAR T-cell therapy responses can be improved, specifically mentioning the humanizing of CAR T-cells to minimize immunogenicity. Dr Gauthier goes on to discuss cytokine-directed therapies such as tocilizumab to minimize the severe toxicities associated with CAR T-cell therapy. He finally goes on to outline how statistical modeling can be harnessed during clinical trials. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
